louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03472846: MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis
Official title: MicroRNAs Levels in Women With Postmenopausal Osteoporosis Under Antiresorptive or Osteoanabolic Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Postmenopausal Osteoporosis
Diabetes Type 2
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
Collaborators: name: St. Vincent Hospital, Vienna
First posted: 2018-03-21
Enrollment: 26
Sex: FEMALE
Minimum age (years): 60
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study is the quantitative determination of bone-specific microRNAs in the serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic therapy.

Detailed description: Primarily the influence of the therapeutic treatment on the microRNA concentration in the serum (treatment-response) and the relation between microRNA serum levels and changes of the bone mineral density will be investigated.

These data will help to examine the use of microRNAs as novel diagnostic biomarkers for the diagnosis of osteoporosis and targeted therapeutic treatment of patients.

Eligibility criteria: Inclusion Criteria:

* Postmenopausal women
* Age 60-80 years
* T-score according to DXA: \<-2.5
* indication for osteoporosis therapy according to international guidelines

Exclusion Criteria:

* Diabetes mellitus type 1
* renal insufficiency III-V °
* Cirrhosis hepatis (Child B or higher)
* Chronic alcohol abuse
* rheumatic disease (RA, SpA, SLE)
* Malignancies (\<5 years)
* Eating Disorder (anorexia nervosa, bulimia)
* bone-specific pretreatment (DMAB, TPTD, strontium ranelate, SERMs) Bisphosphonate treatment is allowed

Primary outcomes:
measure: detection of microRNA concentration in serum
timeFrame: 24 months
Secondary outcomes:
measure: microRNAs and changes in bone metabolism under treatment
timeFrame: 24 months
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University Vienna; St. Vincent Hospital
Study officials:
References:
Clinical trial NCT00485446: Thrombophilia and Thyroid Autoimmunity in Implantation Failure and Recurrent Miscarriage
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thrombophilia, Thyroid Autoimmunity
Lead sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA
Sponsor class: OTHER
First posted: 2007-06-13
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 37
Standard ages: ADULT
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: This study was designed to evaluate the incidence of both, inherited and adquired thrombophilia, and thyroid autoinmunity in unknown infertility (UI), implantation failure (IF) and recurrent miscarriage (RM). To focus on these particular disorders and to rule out another potential confounding variables, 4 particular groups of women were created. Only young women (\< 38 years old), patients whose previous preimplantation genetic screening (PGS) cycles displayed an acceptable rate of aneploidies, and women without organic uterine abnormality, autoimmune disease or endocrine disorder were included in the study.


Eligibility criteria: Inclusion Criteria:

1. The control group included 32 oocyte donors, 18-35 years old, white caucasian, with normal karyotype, no miscarriages, and previous healthy live born infants without pregnancy complications.
2. The UI group consisted of 31 couples with \> 1 year infertility , \< 38 years of age, normal ovarian function, normal hysterosalpingography and transvaginal ultrasound scan of the uterus and ovaries, normal karyotype in both parents, and normozoospermia.
3. The IF group included 26 couples with 3.9±1.1 IVF failures with embryo transfer of at least 2 good quality embryos. They were \< 38 years old, white caucasian, and had normal uterus by vaginal ultrasound and/or hysterosalpingography/ hysteroscopy. Moreover, endocrine disorders or autoimmune diseases were ruled out, a normal karyotype was found in both parents. The male had a sperm concentration \> 5 mill/ml.They also had a PGS cycle with ≥ 60% of normal embryos.
4. The group of women with RM (n = 30) had 3.2±1.3 (range: 2-9) previous miscarriages. They were \< 38 years old, white caucasian, with normal uterus by vaginal ultrasound and/or hysterosalpingography/ hysteroscopy. Also, no endocrine anomalies or autoimmune diseases were found, and both parents had normal karyotype. Sperm concentration was \> 5 mill/ml. Only 6 women had 2 miscarriages (20%) and the remaining 24 women at least 3. They also had a PGS cycle with ≥ 60% of normal embryos.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: Ivi Valencia
Study officials:
affiliation: IVI Valencia
name: Jose Bellver, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01265446: Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.
Official title: A Randomized, Double-blind, Parallel Group, Single-dose Study of the Efficacy of Lidocaine 8 mg + Cetylpyridinium Chloride (CPC) 2 mg Fixed Combination Lozenges on Sore Throat Pain Intensity Compared to Lozenges Containing Lidocaine 1 mg and CPC 2 mg in Subjects With Sore Throat Due to Upper Respiratory Tract Infection.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Sore Throat Due to a Common Cold
Keywords: Sore throat, upper respiratory tract infection, lozenge with lidocaine and cetylpyridinium chloride.
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2010-12-23
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will compare the efficacy and safety of a single dose of a lidocaine 8 mg + cetylpyridimium chloride (CPC) 2 mg lozenge with a single dose of a lidocaine 1 mg + CPC 2 mg lozenge in the treatment of sore throat due to a common cold.


Eligibility criteria: Inclusion Criteria:

* Patients with sore throat due to an upper respiratory tract infection, with recent onset (within 48 hours)
* Sore throat of at least moderate pain intensity

Exclusion Criteria:

* - History of hypersensitivity to any of the study drugs and listed excipients or to drugs of similar chemical classes
* Evidence of mouth breathing or severe coughing
* Evidence of overt oropharyngeal bacterial or fungal infection or evidence of lower respirator tract infection
* Severe renal, liver or cardiac impairment
* Severe lung disease

Primary outcomes:
measure: Change From Baseline Sore Throat Pain Intensity
timeFrame: Baseline and 2 hours post-dose
Secondary outcomes:
measure: Change From Baseline Sore Throat Pain Intensity up to 240 mn Post-dose
timeFrame: Baseline and 240 mn post-dose
Other outcomes:
Locations:
city: Erfurt
country: Germany
facility: Socratec
Study officials:
affiliation: SocraTec R&D GmbH
name: Investigator
role: PRINCIPAL_INVESTIGATOR
References:
citation: Donath F, Mallefet P, Garreffa S, Furcha R. Efficacy of 8 mg lidocaine and 2 mg cetylpyridinium chloride (CPC) fixed-combination lozenges on sore throat pain intensity compared with 1 mg lidocaine and 2 mg CPC fixed-combination lozenges in subjects with sore throat due to upper respiratory tract infection: a randomized double-blind parallel-group single-dose study. Trials. 2018 Dec 12;19(1):679. doi: 10.1186/s13063-018-3077-6.
Clinical trial NCT04399746: Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19
Official title: A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID
Lead sponsor: Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Sponsor class: OTHER_GOV
First posted: 2020-05-22
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Relation 3:1 in Combination:Control groups
Primary purpose: TREATMENT

Brief summary: As the world faces COVID-19, the search for effective treatments against the disease and its complications has turned its gaze to drugs that are classically used in other infectious diseases. Some drugs are being examined for the recent evidence on its effects on viral replication and inflammation, one is Azithromycin, used to treat a wide variety of bacterial infections, Ivermectin, an anti-parasitic drug and the other is Cholecalciferol to increase serum concentration of 25-hydroxyvitamin D.

Detailed description: The aim of the study is to assess the efficacy of Ivermectin-Azithromycin-Cholecalciferol combination in COVID-19 in early stages of the disease with outpatient management.

Enrollment of subject into the trial shall only occur after providing written permission to voluntarily participate into the study by signing and dating the informed consent form before starting any trial related treatment. 30 cases of COVID-19 will be enrolled into the trial with a 3:1 proportion, divided into two groups. First group with confirmed cases of COVID-19 shall be treated with Ivermectin (6mg once daily in day 0,1,7 and 8) plus Azithromycin (500mg once daily for 4 days) plus Cholecalciferol (400 IU twice daily for 30 days) in an outpatient regimen. The second group with confirmed cases of COVID-19 who refused treatment were shall be allocated as the control group for monitoring.

Test for virus at day 1 and 14 from beginning of trial drug started for the outpatient regimen.

Clinical symptoms, oxygen saturation and oxygenation index will be monitored every day of the trial.

Eligibility criteria: Inclusion Criteria:

* Confirmed infection of SARS-CoV2 virus
* Mild COVID-19
* Symptoms of respiratory illness
* Cough
* Fever (T \>38 °C)

Exclusion Criteria:

* Allergy to any of the drugs treatment

Primary outcomes:
measure: Viral clearance
timeFrame: 14 days
Secondary outcomes:
measure: Symptoms duration
timeFrame: 14 days
measure: SpO2
timeFrame: 14 days
measure: SpO2/FiO2
timeFrame: 14 days
Other outcomes:
Locations:
city: Mexico City
country: Mexico
facility: Outpatient treatment
Study officials:
References:
Clinical trial NCT00252746: ZD6474 Phase IIa Dose Finding Multicentre Study
Official title: A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum [Title Abbreviated]
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Non Small Cell Lung Carcinoma
Keywords: NSCLC
Non Small Cell Lung Cancer
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2005-11-15
Enrollment: 53
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively


Eligibility criteria: Inclusion Criteria:

* Provision of written informed consent.
* Life expectancy of 12 weeks or longer.

Exclusion Criteria:

* Pregnancy, breast feeding or female patients wishing to become pregnant.
* Treatment with a non-approved or investigational drug within 30 days before enrolment

Primary outcomes:
measure: To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
timeFrame: Every 4 weeks for the first 24 weeks of treatment and then every 8 weeks until PD is determined or withdrawal due to any reasons other than PD. If PR or CR is observed, tumour assessment will be repeated 4 weeks after for confirmation of the response
Secondary outcomes:
measure: To assess the tolerability, safety, disease control rate, duration of response, time to progression, changes in quality of life and tumour-related and overall symptom improvements, and to characterise the PK and PK-PD relationship
timeFrame: Every 4 weeks till meeting discontinuation criteria
Other outcomes:
Locations:
city: Matsuyama
country: Japan
facility: Research Site
state: Ehime
city: Isehara
country: Japan
facility: Research Site
state: Kanagawa
city: Osakasayama
country: Japan
facility: Research Site
state: Osaka
city: Toyonaka
country: Japan
facility: Research Site
state: Osaka
city: Sunto-gun
country: Japan
facility: Research Site
state: Shizuoka
city: Okayama
country: Japan
facility: Research Site
city: Tokyo
country: Japan
facility: Research Site
Study officials:
affiliation: Sanofi
name: Clinical Sciences & Operations
role: STUDY_DIRECTOR
References:
citation: Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 2008 Apr;3(4):386-93. doi: 10.1097/JTO.0b013e318168d228.
Clinical trial NCT02244346: Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)
Official title: Secotex®: Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostatic Hyperplasia
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-09-19
Enrollment: 811
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients treated with Secotex® in the daily clinical practice

Brief summary: Study to evaluate the safety profile of Secotex® in the improvement of the symptoms of Benign Prostatic Hyperplasia in real clinical practice


Eligibility criteria: Inclusion Criteria:

* Patients of any age with a diagnosis of symptomatic Benign Prostatic Hyperplasia (BPH)
* Patients with symptoms, that according to physician require medical treatment to improve quality of life
* Patients could be naive to treatment or could be on treatment with other drugs but have not responded adequately to treatment

Exclusion Criteria:

* Patients with known hypersensitivity to Tamsulosin, or any other component of the product
* Patients with a history of orthostatic hypotension or severe liver failure

Primary outcomes:
measure: Number of patients with adverse events
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03809546: Individual Differences in Drug Response
Official title: Differential Female Response to Δ9-tetrahydrocannabinol (THC): The Influence of Estradiol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2019-01-18
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Females are increasingly using cannabis, yet remain underrepresented in preclinical and clinical cannabinoid research. This female-specific research plan will test the effects of two recreationally relevant doses of oral THC and placebo in healthy females at two phases of the menstrual cycle. Acute oral THC will be administered in a double-blind and counterbalanced design. Menstrual cycle phase will be determined using blood serum analyses of estradiol and progesterone and self-reported responses. The main hypothesis is circulating estradiol levels are associated with cardiac, neuroendocrine, and subjective THC response. The rationale for the presented work is to better understand the risks of cannabis use, in order to maximize possible medical potential and minimize public health risks. The expected outcome of this work is a deeper understanding of how circulating estradiol levels may associate with response to THC and how the physiological response is associated with the subjective response. Uncovering the individual differences in response to THC will allow for more preventive action against cannabis-induced anxiety, paranoia, and psychosis.


Eligibility criteria: Inclusion Criteria:

* 18-35 years old, females (N=60)
* Body Mass Index 19-26
* High school education, fluent in English
* Occasional cannabis users ( \<11 times in past 30 days)

Exclusion Criteria:

* History of daily cannabis use
* Past or present severe substance use disorder
* Current or past diagnosis with drug treatment for psychosis/bipolar/schizophrenia
* Past year major depression
* Current or past Post Traumatic Stress Disorder
* Attention Deficit Hyperactivity Disorder
* Cardiovascular illness, high blood pressure, abnormal electrocardiagram
* Current medications (NO hormonal birth control or intrauterine device)
* Pregnant or planning to become pregnant

Primary outcomes:
measure: Change From Baseline in Profile of Mood States (POMS)
timeFrame: Difference from baseline (time 0 or pre-capsule) to post-capsule (120 min)
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: Elisa Pabon
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00634946: SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation
Official title: A Multicenter, Randomized, Double-blind Recommended Dose-finding Study of SI-6603 in Patients With Lumbar Disc Herniation (Phase II/III Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Lumbar Vertebra Hernia
Keywords: Chemonucleolysis
Lumbar Vertebrae
Hernia
Lead sponsor: Seikagaku Corporation
Sponsor class: INDUSTRY
First posted: 2008-03-13
Enrollment: 195
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether SI-6603 is effective in the treatment of lumbar disc herniation.


Eligibility criteria: Inclusion Criteria:

* Patients with lumbar disc herniation (L4-L5 or L5-S1) as assessed by MRI and clinical symptoms corresponding to position of the impaired nerve root
* Patients assessed as positive in the SLR test
* Patients with sciatica in either lower leg
* Patients with no improvement from pharmacotherapy or concomitant treatment with drug and nerve block

Exclusion Criteria:

* Patients who have 2 or more lumbar disc herniations as assessed by MRI
* Patients with "extrusion-type" or "sequestration-type" herniation in whom a rupture into the posterior longitudinal ligament is identified by MRI
* Patients who have received nerve block within 3 weeks before screening
* Patients who have undergone lumbar operation, chemonucleolysis, or percutaneous nucleotomy

Primary outcomes:
measure: Changes in leg pain from baseline.
timeFrame: 13 weeks
Secondary outcomes:
measure: The leg pain
timeFrame: At each assessment time point
Other outcomes:
Locations:
city: Chubu
country: Japan
facility: Chubu Area
city: Chugoku
country: Japan
facility: Chugoku Area
city: Hokkaido
country: Japan
facility: Hokkaido Area
city: Kansai
country: Japan
facility: Kansai Area
city: Kanto
country: Japan
facility: Kanto Area
city: Kyushu
country: Japan
facility: Kyushu Area
city: Shikoku
country: Japan
facility: Shikoku Area
city: Tohoku
country: Japan
facility: Tohoku Area
Study officials:
References:
citation: Matsuyama Y, Chiba K, Iwata H, Seo T, Toyama Y. A multicenter, randomized, double-blind, dose-finding study of condoliase in patients with lumbar disc herniation. J Neurosurg Spine. 2018 May;28(5):499-511. doi: 10.3171/2017.7.SPINE161327. Epub 2018 Feb 9.
Clinical trial NCT04451746: The Influence of Combined Oral Contraception on the DEvelopment and progRession of Chronic venoUs diSeases
Official title: The Influence of Combined Oral Contraception on the DEvelopment and progRession of Chronic venoUs diSeases
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Chronic Venous Diseases
Lead sponsor: Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia
Sponsor class: OTHER
First posted: 2020-06-30
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: Investigation of the influence of combined oral contraception on the development and progression of chronic venous diseases


Eligibility criteria: Inclusion Criteria:

1. The investigators consistently include patients who have been prescribed hormonal tablets for contraception, namely 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
2. Clinical class C0-1 according to CEAP;

2) Able to come for checkups every 3 months; 3) The presence of informed consent.

Exclusion Criteria:

1. Age up to 45 years;
2. A history of surgical treatment of veins of the lower extremities;
3. Clinical class C2 and higher according to CEAP;
4. History of DVT or PE;
5. Aplasia or angio-dysplasia of deep veins;
6. Restriction of mobility;
7. Arterial insufficiency;
8. Oncological diseases.

Primary outcomes:
measure: Development and progression of chronic venous diseases
timeFrame: 1 year
Secondary outcomes:
measure: Deep venous thrombosis
timeFrame: 1 year
Other outcomes:
Locations:
city: Chelyabinsk
country: Russian Federation
facility: Clinic of phlebology and laser surgery
Study officials:
affiliation: South Ural State Medical University
name: Alexey Fokin
role: STUDY_CHAIR
References:
Clinical trial NCT03219346: The Effectiveness of Oral Health in Improving Dysphagia of Patients After Stroke of Swallowing Function and Oral Health Quality of Life
Official title: The Effectiveness of Oral Health in Improving Dysphagia of Patients After Stroke of Swallowing Function and Oral Health Quality of Life
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Swallowing Disorders
Stroke
Keywords: stroke , swallowing function ,oral health quality of life
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2017-07-17
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The prevalence of chewing dysphagia in the domestic rehabilitation department ward was about 53.61%.Nasal tube retention of about 31%, due to nasogastric tube feeding, often overlooked oral hygiene, easy to cause respiratory tract infection. At the same time, oral hygiene will also affect the effectiveness of swallowing treatment, is worthy of attention to health problems.


Eligibility criteria: Inclusion Criteria:

1. Clinical diagnosis of first stroke with nasal tube retention
2. Language therapist providing swallowing treatment
3. Caregiver providing oral care to patients

Exclusion Criteria:

1. Oral cancer
2. head and neck cancer

Primary outcomes:
measure: Functional oral intake scale
timeFrame: before the first swallowing treatment (one day before treatment)
Secondary outcomes:
measure: Functional oral intake scale
timeFrame: two weeks after the swallowing treatment (14 days)
measure: Functional oral intake scale
timeFrame: three weeks after the swallowing treatment (21 days)
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Chang Gung University
Study officials:
affiliation: Chang Gung University
name: Tzu-Ting Hung
role: STUDY_DIRECTOR
References: